Biosimilar partnerships for Alvotech and Pall Biotech

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Biosimilar partnerships for Alvotech and Pall Biotech

INICIO/Noticias Farmacéuticas | Posted 19/10/2018 0 Post your comment

Partnering to develop biosimilars is still in vogue. The latest companies to join the trend include Alvotech with Changchun High & New Technology Industries Group (CCHN) and Pall Corporation’s Biotech business (Pall Biotech) with Aetos Biologics.

US-based filtration, separation and purification specialist Pall Corporation, announced on 12 September 2018 a strategic partnership between its Pall Biotech business unit and US-based Aetos Biologics, a biosimilar cell-line development company.

The collaboration between the companies aims to offer biosimilar manufacturing solutions to the global biosimilars market. Pall Biotech will provide access to next-generation bioprocess equipment, such as the Allegro STR Single-use Stirred Tank Bioreactor for good manufacturing practice (GMP) manufacturing, and consumables to enable efficient biosimilar production. Aetos Biologics will provide high quality/high-titre cell lines and scalable manufacturing processes.

Separately, Iceland-based biopharmaceutical company Alvotech announced on 26 September 2018 that it was entering into a joint venture with China-based CCHN which will enable Alvotech to develop, manufacture and commercialize its biosimilar portfolio in China.

The deal includes construction of a jointly-owned facility, which is expected to start in the first half of 2019. Under the terms of the agreement, CCHN will fund the joint venture with US$100 million while Alvotech will contribute additional capital and six drug market authorizations for its monoclonal antibodies, valued at US$100 million.

Robert Wessman, Alvotech’s founder said that ‘the partnership forms a leading biosimilar force in China’ and gives Alvotech ‘access to the second largest and fastest growing pharma market in the world an important step given our goal of becoming a leading company for biosimilars in the Chinese market’.

Back in December 2013, the company invested US$250 million to build a plant in Reykjavik for the development and manufacture of a portfolio of biosimilar monoclonal antibodies [1]. The plant opened in June 2016. Alvotech also made a deal with US-based bio-process management company Finesse Solutions (Finesse) in March 2014 for bio-manufacturing [2].

Related articles
Teva and Celltrion to partner on biosimilars

Partnership between PlantForm and Guelph University for biosimilar trastuzumab

Huahai and Oncobiologics make biosimilars deal

References
1. GaBI Online - Generics and Biosimilars Initiative. Alvotech invests US$250 million in biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Oct 20]. Available from: www.gabionline.net/Biosimilars/News/Alvotech-invests-US-250-million-in-biosimilars
2. GaBI Online - Generics and Biosimilars Initiative. Alvotech and Finesse enter into biosimilars collaboration [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Oct 20]. Available from: www.gabionline.net/Biosimilars/News/Alvotech-and-Finesse-enter-into-biosimilars-collaboration

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Alvotech, Pall Biotech